Cortagen is a Khavinson short-peptide bioregulator associated with the cerebral cortex and nervous tissue, studied in Russian bioregulation literature for neural repair and recovery. Community use centers on neuroprotection and cognitive support, though reports are limited and confidence is low. The typical community protocol involves 650 mcg daily, with no standardized timing or cycling reported, and all human use remains off-label or compounded due to lack of FDA approval. No specific side effects have emerged as a consistent theme in community reporting.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Cortagen has no human clinical evidence; all available data come from preclinical or mechanistic research in animals. The single indication mapped is limited to animal-only studies, with no registered trials or completed human studies to date. This absence of human data means any application in people remains unsupported by clinical evidence.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 2 out-of-stock offers not shown
How Cortagen is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Based on a single community report, users take Cortagen subcutaneously once daily, with amounts ranging from 650 mcg up to 10 mg per day.